Our featured projects
Working to address India’s most pressing needs
PATH’s projects in India focus on maternal and child health, reproductive health, emerging and epidemic diseases, health technologies, and vaccines and immunization. They include:
Advancing rotavirus vaccine development project
We are working toward the development of new, safe, effective, and affordable vaccines to reduce deaths and illness due to diarrheal disease caused by rotavirus. PATH has supported several vaccine manufacturers in India in establishing manufacturing systems, providing technical guidance, and conducting clinical studies of rotavirus vaccine candidates. We are working with Bharat Biotech International, Ltd. to conduct a Phase 3 efficacy clinical trial of their rotavirus vaccine and helping Serum Institute of India, Ltd. prepare for a Phase 3 efficacy trial. We are also supporting the establishment of Christian Medical College, Vellore as a reference laboratory for the development of rotavirus vaccines.
Evaluating and improving consumer appeal of oral rehydration solution and zinc
With our Technology Solutions global program, we’re working to reduce the burden of diarrhea among children younger than five years of age in developing countries. We’re identifying potential improvements to the taste, packaging, and labeling of oral rehydration solution and zinc treatments to increase appeal, demand, and use without sacrificing function.
India TB program
With funding from the US Agency for International Development, PATH provides short- and long-term technical assistance to countries with high burdens of tuberculosis (TB). In India, we support national TB control efforts, including laboratory accreditation for solid culture and drug susceptibility testing to accelerate India’s response to multidrug-resistant TB. We are piloting national infection control guidelines at the state level in Andhra Pradesh and rolling out an advocacy and communications plan to address local challenges in controlling TB.
Japanese Encephalitis Project
PATH has been providing technical assistance to the Government of India and 15 Indian states for planning and implementation of the Japanese encephalitis (JE) vaccination program. Our key areas of work have been in surveillance, advocacy, capacity-building, and monitoring and evaluation as well as providing evidence-based policy solutions for a strengthened JE vaccination program. PATH also supported the Government of India in negotiating the price of the JE vaccine with the vaccine manufacturer and helped make the vaccine affordable in India. Through our partnership with the central and state governments, about 78 million Indian children have been vaccinated against JE, the leading cause of viral disability and death among children in Asia and the Western Pacific.
Meningococcal conjugate vaccines
In partnership with our Vaccine Development global program, we’re working with the Serum Institute of India Ltd. on development of an affordable, thermostable vaccine that would protect against five types of meningitis: A, C, W, Y, and X. The vaccine is being developed for use in sub-Saharan Africa.
The Oxytocin Initiative aims to improve maternal health and survival in poor settings by gathering evidence that may support expanded, safe use of oxytocin, a drug recommended by the World Health Organization for the prevention and treatment of postpartum hemorrhage. We are also exploring the administration of oxytocin through the PATH-developed Uniject™ injection system.
Project Parivartan: empowering and mobilizing communities for sustainable improvements in health outcomes in Bihar
We are assisting prime contractor Project Concern International in establishing a knowledge base of successful approaches to support scaling up and sustaining community mobilization efforts.
Safe Water Project
The Safe Water Project is assessing gaps in the household water treatment and safe storage market. We’re determining how well the private sector can fill these gaps in a commercially sustainable manner while providing safe drinking water to vulnerable populations. In collaboration with manufacturers, we implemented pilot projects across Tamil Nadu, Madhya Pradesh, Andhra Pradesh, and Uttar Pradesh to test distribution models that may result in better market penetration among low-income households.
Through pilot projects, we tested a microfinance model that links manufacturers or marketers who have affordable, effective products with a microfinance institution that can provide credit so people in low-income households may purchase the product. We reached commercially sustainable levels of penetration in most pilot variations.
We are using information and insights from this extended user testing study to inform the development of functional product prototypes designed specifically for low-income users in India. The study results are informing marketing strategies for low-income households that have little experience with water treatment. We are also partnering with private-sector manufacturers for production and commercialization of the device prototypes to improve the availability of appropriate products in areas with the highest need while minimizing cost to the consumer.
PATH is working with the Indian Council for Medical Research, the state governments of Andhra Pradesh and Gujarat, and other partners to gather information that will help India establish a comprehensive cervical cancer prevention plan. The plan will include primary prevention—such as vaccines—and secondary prevention—such as screening and treatment. PATH is also working with government research agencies to evaluate and demonstrate a new, rapid test designed for low-resource settings to detect strains of human papillomavirus that cause most cervical cancer.
Strengthening routine immunization systems in Mumbai and Madhya Pradesh
In two separate but related projects, PATH is improving the quality and reach of immunization services to reduce deaths of children from vaccine-preventable diseases. In the slums of Mumbai, we’re strengthening immunization service delivery in five health posts. In Madhya Pradesh, we are working to increase coverage of childhood vaccines from 36 to 70 percent.
Ultra Rice® technology
PATH’s Ultra Rice technology packs vitamins and minerals into manufactured “grains” made from rice flour. More than 28 studies in eight countries form the evidence base for Ultra Rice technology. In India, we’ve established the safety and efficacy of Ultra Rice technology. We are now working to strengthen the supply chain, build quality control systems, and model large-scale introduction through public-sector distribution channels.
Ultra Rice is a registered trademark of Bon Dente International, Inc., in the United States.